Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
CME/CE Virtual Event
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
0.50 credits
Axatilimab’s Impact on cGVHD and Associated BOS
Axatilimab’s Impact on cGVHD and Associated BOS
Project Oncology®
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Amandeep Salhotra, MD
Real-World Outcomes with Axatilimab in cGVHD
Real-World Outcomes with Axatilimab in cGVHD
Project Oncology®
Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP; Hana Safah, MD
- Brian P. McDonough, MD, FAAFP
- Hana Safah, MD
CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
0.75 credits
CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits

Medical News

Medical News
Busulfan AUC Thresholds Linked to Pediatric HSCT Event-Free Survival
08/07/2026
Read more
Medical News
Real-World First-Line Alk Tki Comparisons in Alk-Positive Nsclc
08/03/2026
Read more
Medical News
36-Month Relapse Window May Define High-Risk Myeloma
07/30/2026
Read more
Medical News
Financial Toxicity Common in Insured Brazilian Cancer Patients
07/28/2026
Read more

CME/CE

Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
CME/CE
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP; Tiffany Traina, MD
0.50 credits
- Sara A. Hurvitz, MD, FACP
- Tiffany Traina, MD
0.50 credits
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
MinuteCE®
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits

Clinical Practice

Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Project Oncology®
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Project Oncology®
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Project Oncology®
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?

Programs

Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Project Oncology®
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
CME/CE Virtual Event
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Multiple dates available
0.75 credits
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
MinuteCE®
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
MinuteCE®
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits